RecruitingPHASE1, PHASE2NCT07281976
A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer
Studying Chronic bilirubin encephalopathy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Nanjing Leads Biolabs Co.,Ltd
- Principal Investigator
- yongmei YinThe First Affiliated Hospital with Nanjing Medical University
- Intervention
- LBL-024 for Injection(drug)
- Enrollment
- 220 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2026 – 2027
Study locations (7)
- Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
- Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
- Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
- Henan Cancer Hospital, Zhengzhou, Henan, China
- Jiangsu Province Hospital, Nanjing, Jiangsu, China
- The first hospital of Jilin University, Changchun, Jilin, China
- Liaoning Cancer Hospital, Shenyang, Liaoning, China
Collaborators
The First Affiliated Hospital with Nanjing Medical University
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07281976 on ClinicalTrials.govOther trials for Chronic bilirubin encephalopathy
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07342478ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLLNewave Pharmaceutical Inc
- RECRUITINGPHASE2NCT07530445Phase II Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Albumin-Bound Paclitaxel and Lenvatinib as Second-Line Therapy for Unresectable or Metastatic Biliary Tract CancerSun Yat-sen University
- RECRUITINGPHASE2NCT07537660Auricular Point Stimulation Plus Dexamethasone for Nausea and Vomiting Caused by Gemcitabine Plus PaclitaxelSecond Affiliated Hospital, School of Medicine, Zhejiang University
- RECRUITINGNCT03537794Characterizing Dopamine Receptor Binding in Treatment Resistant DepressionUnity Health Toronto
- RECRUITINGPHASE1NCT07096869Bioequivalence Study of Paclitaxel Protein-bound Particles for Injectable Suspension (Albumin-bound) in Breast Cancer PatientsCSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
- RECRUITINGPHASE2NCT06947291Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid TumorsCSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- RECRUITINGNANCT06765590Bioequivalence Study of Paclitaxel for Injection (Albumin Bound) in Subjects With Breast CancerSichuan Huiyu Pharmaceutical Co., Ltd
- RECRUITINGNANCT06856200A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast CancerFudan University